Saskia Middeldorp, ASH 2022: The efficacy of low-molecular-weight heparin in women with recurrent miscarriage and inherited thrombophilia – the ALIFE 2 trial

Studies have linked recurrent miscarriage with inherited thrombophilia. The ALIFE 2 trial aimed to assess the efficacy of low-molecular-weight heparin (LMWH) therapy in women with recurrent miscarriage and inherited thrombophilia. In this touchONCOLOGY interview, we speak with Professor Saskia Middeldorp (Radboud University Medical Center, Nijmegen, Netherlands) to discuss the ALIFE 2 clinical trial and the impact the findings have for women with inherited thrombophilia. 

The abstract entitled ‘Low-Molecular-Weight Heparin Versus Standard Pregnancy Care for Women with Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An Open-Label, Phase III Randomized Controlled Trial’ (Abstract #LB-5) was presented at ASH Annual Meeting, 10–13, December, 2022.

Questions:

1. What was known about the use of anticoagulants to reduce adverse pregnancy outcomes in women with inherited thrombophilia? (0:18)
2. What were the aims, design and eligibility criteria of the ALIFE 2 clinical trial? (2:04)
3. What were the primary and secondary outcome measures and how well were they achieved in the two groups? (2:45)
4. On the basis of these findings, what advice would you give to women with confirmed inherited thrombophilia, with recurrent pregnancy loss? (4:17)
5. What further research is needed? (5:41)

Disclosures: Saskia Middeldorp is on the advisory board and has received honoraria from Aspen, Pfizer and Viatris. She has received grant/research support from Aspen and Pfizer.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed as a highlight of ASH 2022

Access more content on Haematology